139 related articles for article (PubMed ID: 36330637)
1. Exploring Cantharidin and its Analogues as Anticancer Agents: A Review.
Li S; Wu X; Fan G; Du K; Deng L
Curr Med Chem; 2023; 30(18):2006-2019. PubMed ID: 36330637
[TBL] [Abstract][Full Text] [Related]
2. Overview of Cantharidin and its Analogues.
Wang G; Dong J; Deng L
Curr Med Chem; 2018; 25(17):2034-2044. PubMed ID: 28413963
[TBL] [Abstract][Full Text] [Related]
3. Use of different ligand modification liposomes to evaluate the anti-liver tumor activity of cantharidin.
Zou M; Xu Y; Lin P; Zhou L; Xia X
J Liposome Res; 2023 Sep; 33(3):283-299. PubMed ID: 36594207
[TBL] [Abstract][Full Text] [Related]
4. Development of Glycyrrhetinic Acid and Folate Modified Cantharidin Loaded Solid Lipid Nanoparticles for Targeting Hepatocellular Carcinoma.
Xu Y; Wang M; Ning S; Yang Z; Zhou L; Xia X
Molecules; 2022 Oct; 27(20):. PubMed ID: 36296377
[TBL] [Abstract][Full Text] [Related]
5. Enhanced anticancer efficacy of cantharidin by mPEG-PLGA micellar encapsulation: An effective strategy for application of a poisonous traditional Chinese medicine.
Yao H; Zhao J; Wang Z; Lv J; Du G; Jin Y; Zhang Y; Song S; Han G
Colloids Surf B Biointerfaces; 2020 Dec; 196():111285. PubMed ID: 32771818
[TBL] [Abstract][Full Text] [Related]
6. Anticancer Attributes of Cantharidin: Involved Molecular Mechanisms and Pathways.
Naz F; Wu Y; Zhang N; Yang Z; Yu C
Molecules; 2020 Jul; 25(14):. PubMed ID: 32707651
[TBL] [Abstract][Full Text] [Related]
7. Development of 11-DGA-3-
Zhou L; Zou M; Zhu K; Ning S; Xia X
Molecules; 2019 Aug; 24(17):. PubMed ID: 31450608
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic effects of cantharidin analogues without bridging ether oxygen on human hepatocellular carcinoma cells.
Yeh CB; Su CJ; Hwang JM; Chou MC
Eur J Med Chem; 2010 Sep; 45(9):3981-5. PubMed ID: 20691337
[TBL] [Abstract][Full Text] [Related]
9. Anticancer effects of cantharidin in A431 human skin cancer (Epidermoid carcinoma) cells in vitro and in vivo.
Li CC; Yu FS; Fan MJ; Chen YY; Lien JC; Chou YC; Lu HF; Tang NY; Peng SF; Huang WW; Chung JG
Environ Toxicol; 2017 Mar; 32(3):723-738. PubMed ID: 27113412
[TBL] [Abstract][Full Text] [Related]
10. Cantharidin-encapsulated thermal-sensitive liposomes coated with gold nanoparticles for enhanced photothermal therapy on A431 cells.
Wang S; Xin J; Zhang L; Zhou Y; Yao C; Wang B; Wang J; Zhang Z
Int J Nanomedicine; 2018; 13():2143-2160. PubMed ID: 29692611
[TBL] [Abstract][Full Text] [Related]
11. 18-GA-Suc Modified Liposome Loading Cantharidin for Augmenting Hepatic Specificity: Preparation, Characterization, Antitumor Effects, and Liver-Targeting Efficiency.
Zhu K; Zhou L; Zou M; Ning S; Liu S; Zhou Y; Du K; Zhang X; Xia X
J Pharm Sci; 2020 Jun; 109(6):2038-2047. PubMed ID: 32173319
[TBL] [Abstract][Full Text] [Related]
12. The natural anticancer agent cantharidin alters GPI-anchored protein sorting by targeting Cdc1-mediated remodeling in endoplasmic reticulum.
Sahu PK; Tomar RS
J Biol Chem; 2019 Mar; 294(11):3837-3852. PubMed ID: 30659098
[TBL] [Abstract][Full Text] [Related]
13. Non-ionic surfactant vesicles simultaneously enhance antitumor activity and reduce the toxicity of cantharidin.
Han W; Wang S; Liang R; Wang L; Chen M; Li H; Wang Y
Int J Nanomedicine; 2013; 8():2187-96. PubMed ID: 23807847
[TBL] [Abstract][Full Text] [Related]
14. Anticancer activity and protein phosphatase 1 and 2A inhibition of a new generation of cantharidin analogues.
Sakoff JA; Ackland SP; Baldwin ML; Keane MA; McCluskey A
Invest New Drugs; 2002 Feb; 20(1):1-11. PubMed ID: 12003183
[TBL] [Abstract][Full Text] [Related]
15. The effects of cantharidin and cantharidin derivates on tumour cells.
Liu D; Chen Z
Anticancer Agents Med Chem; 2009 May; 9(4):392-6. PubMed ID: 19442040
[TBL] [Abstract][Full Text] [Related]
16. Cantharidin suppresses gastric cancer cell migration/invasion by inhibiting the PI3K/Akt signaling pathway via CCAT1.
Song M; Wang X; Luo Y; Liu Z; Tan W; Ye P; Fu Z; Lu F; Xiang W; Tang L; Yao L; Nie Y; Xiao J
Chem Biol Interact; 2020 Feb; 317():108939. PubMed ID: 31945315
[TBL] [Abstract][Full Text] [Related]
17. Hepatotoxic mechanism of cantharidin: insights and strategies for therapeutic intervention.
Jin D; Huang NN; Wei JX
Front Pharmacol; 2023; 14():1201404. PubMed ID: 37383714
[TBL] [Abstract][Full Text] [Related]
18. Cantharidin induces G2/M phase arrest and apoptosis in human colorectal cancer colo 205 cells through inhibition of CDK1 activity and caspase-dependent signaling pathways.
Huang WW; Ko SW; Tsai HY; Chung JG; Chiang JH; Chen KT; Chen YC; Chen HY; Chen YF; Yang JS
Int J Oncol; 2011 Apr; 38(4):1067-73. PubMed ID: 21271215
[TBL] [Abstract][Full Text] [Related]
19. Cantharidin analogues: synthesis and evaluation of growth inhibition in a panel of selected tumour cell lines.
McCluskey A; Ackland SP; Bowyer MC; Baldwin ML; Garner J; Walkom CC; Sakoff JA
Bioorg Chem; 2003 Feb; 31(1):68-79. PubMed ID: 12697169
[TBL] [Abstract][Full Text] [Related]
20. Augmented Anticancer Effects of Cantharidin with Liposomal Encapsulation: In Vitro and In Vivo Evaluation.
Zhang X; Lin CC; Chan WK; Liu KL; Yang ZJ; Zhang HQ
Molecules; 2017 Jun; 22(7):. PubMed ID: 28672816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
